Etihad Cargo loading CSafe RAP Container for large pharmaceutical shipments

Etihad Cargo and long-term partner CSafe Global, a provider of closed cool-chain solutions under its PharmaLife product, are to introduce high-performing temperature-controlled across all Etihad Cargo’s global fleet of wide-body and freighter aircraft flights to deliver additional payload protection for large pharmaceutical shipments.

The CSafe RAP uses innovative heating and compressor-driven cooling technologies, along with advanced VIP insulation, to maintain constant payload temperatures even at extreme ambient temperatures spanning from -30°C to +54°C. Its large payload compartment of 6.68m3 easily accommodates up to four standard US pallets or five standard Euro pallets. With an extended battery run time of more than 120 hours, the CSafe RAP ensures temperature integrity and product viability through to destination even on extended journeys.

Etihad Cargo, which has recently reinforced its pharmaceutical logistics expertise with the launch of PharmaLife, a specialised pharma and healthcare product, was the first carrier in the Middle East to receive IATA’s CEIV (Centre of Excellence for Independent Validators) certification in pharmaceutical logistics. Following a vigorous testing process, the carrier has now approved the use of the CSafe RAP on its aircrafts to offer customers continued assurance of compliance and temperature-control along with the largest payload capacity in the industry.

“As an IATA CEIV Pharma certified carrier, we take the transportation and handling of pharmaceutical shipments very seriously, adhering to the strictest processes with the very best in class equipment that ensures the best quality handling in the quickest time,” said Fabrice Panza, Manager Global Cool Chain Solutions at Etihad Cargo. “The addition of the CSafe RAP further enhances our customer offering by completing our active cool chain portfolio. Through this partnership we are now able to provide the largest and most high-tech solutions of active containers worldwide.

“We are confident as market demands become stronger for vaccines and clinical trials that we are ready to offer quality along with enough capacity to our customers,” Panza added.

Leave a Reply